Cognition Therapeutics is a clinical-stage biopharmaceutical company. Co. is developing a pipeline of small molecule product candidates that are designed to target the o-2 (sigma-2) receptor (S2R) complex, a key regulator of the cellular damage response for diseases such as Alzheimer's disease, dry Age-Related Macular Degeneration (AMD), geographic atrophy (a form of dry AMD), and other conditions. Co.'s main product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. Co. is initially focused on the development of CT1812 for the treatment of AD by targeting the accumulation of B-amyloid. The CGTX average annual return since 2021 is shown above.
The Average Annual Return on the CGTX average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CGTX average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CGTX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|